At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
APL-2drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Prospective, Study to Assess the Safety, Tolerability, Efficacy and Pharmacokinetics of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)
In Brief
A Phase 2 clinical trial evaluating APL-2 for Warm Autoimmune Hemolytic Anemia and Cold Agglutinin Disease. Completed, enrolled 24 participants across 8 sites.
Detailed Summary
This study is to assess the safety, tolerability, preliminary efficacy, and pharmacokinetics of APL-2 in subjects with warm Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJul 2017
Enrollment StartAug 2017
Primary CompletionSep 2022
TodayJul 2026
First PostedJul 24, 2017
Enrollment StartAug 31, 2017
Primary CompletionSep 12, 2022
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 8.9 years ago
Interventions
APL-2drug
Complement (C3) Inhibitor